查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球中枢神经系统生物标志物市场 - 2023-2030年
市场调查报告书
商品编码
1289774

全球中枢神经系统生物标志物市场 - 2023-2030年

Global Central Nervous System Biomarkers Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球中枢神经系统生物标志物市场规模在2022年达到47.908亿美元，预计到2030年将出现有利可图的增长，达到98.527亿美元。在预测期间（2023-2030年），该市场的年复合增长率为9.7%。

生物标志物或生物标记物是定量测量，提供有关生物过程、疾病状态或对治疗的反应的信息。它们有可能更好地了解某一特定疾病的病因和发病机制，为研究人员和临床医生提供对许多衰弱性疾病的诊断、治疗和预后的宝贵见解。

中枢神经系统生物标志物市场受到一些因素的推动，如结合蛋白质组学、基因组学和中枢神经系统组织、CSF或血液的代谢组学询问，以及成像技术和新型生物标志物的开发。

市场动态

对新型生物标志物的需求不断增加

中枢神经系统疾病的新型潜在生物标志物包括tau蛋白、神经丝轻链（NFL）、胶质纤维酸性蛋白（GFAP）和泛素C端水解物-L1（UCH-L1）。tau蛋白是一种神经轴突标志物，主要位于中枢神经系统的白质中，据报道在缺血性中风和心脏骤停中会增加。NFL在心脏骤停后的预后中具有很高的准确性，但也有报道说它在神经退行性疾病（如阿尔茨海默病）中会增加。

GFAP是一种星形细胞标志物，作为神经保护机制的一部分而产生，并与头部创伤、脑内出血、缺血性中风和心脏骤停后的预后有关。UCH-L1是一种神经元细胞体标记，对脑损伤后的神经轴突稳定性和修复至关重要。

技术的进步加快了生物标志物的发现速度，但大多数生物标志物还没有得到验证。将生物标记物纳入临床试验和实践将有助于提高研究效率，并为个性化神经病学的发展提供信息。

中枢神经系统生物标志物测试和诊断的高成本

随着验证过程的高成本，如样本收集和储存，政府的规则和政策正在改变，因为报销不包括不被认为是标准护理的生物标志物介导的治疗。

即使生物标志物为测试增加了重要的价值，但退款是有限的。例如，拥有5000多万受益人的美国最大的医疗保健保险公司Medicare不资助实验性药品或大多数筛查和生物标志物测试。因此，上述因素预计将在预测期内阻碍市场的增长。

COVID-19影响分析

COVID-19大流行病与一系列神经系统并发症有关，包括认知障碍和神经退行性变化。例如，西弗吉尼亚州的马歇尔大学回顾了与COVID-19有关的各种神经退行性变化，并强调了主要循环生物标志物的重要性，与疾病的进展和严重程度有关。

他们的文献调查表明，重要的中枢神经系统蛋白，如GFAP、NfL和pT181-tau，以及各种炎症细胞因子，在COVID-19患者中都有明显改变。目前对与COVID-19有关的神经病理变化以及生物标志物在识别有可能发展为严重疾病的病人方面的潜在用途的理解是有限的。

俄罗斯-乌克兰冲突分析

关于战争对全球科学界的长期影响以及俄罗斯乌克兰战争期间乌克兰学术、医学和科学学科研究机会的错过的风险。根据FDA的临床试验数据库，乌克兰正在测试251种药品和设备。

根据临床试验数据库，2022年，乌克兰正在进行或计划进行1000多项药物临床试验，其中仅在肿瘤学领域就有786项。战争对俄罗斯的临床试验基地产生了负面影响，因为资源和人力没有按照优先次序分配，导致中枢神经系统护理恶化。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按类型分類的片段
  • 按应用分类的摘要
  • 按疾病分类
  • 按终端用户分类
  • 按地区分类

第4章：动态变化

  • 影响因素
    • 驱动因素
      • 对新型生物标志物的需求不断增加
    • 限制因素
      • 中枢神经系统生物标志物测试和诊断的高成本
    • 机会
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按类型

  • 安全性生物标志物
  • 有效性生物标志物
  • 验证性生物标志物
  • 其他类型

第八章：按应用分类

  • 药物发现和开发
  • 个人化药物
  • 疾病风险评估
  • 诊断学
  • 其他

第九章：按疾病分类

  • 多发性硬化症
  • 阿尔茨海默氏病
  • 帕金森病
  • 创伤性脑损伤
  • 其他疾病

第十章：按终端用户分类

  • 诊断实验室
  • 诊所
  • 医院
  • 研究中心
  • 其他机构

第十一章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第十二章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十三章 ：公司简介

  • Acumen Pharmaceuticals Inc.
    • 公司概述
    • 产品组合和说明
    • 财务概况
    • 主要发展情况
  • Biogen Inc.
  • Alseres Pharmaceuticals Inc.
  • Aposense Ltd.
  • Avacta Life Sciences Ltd.
  • Banyan Biomarkers Inc.
  • Bio-Rad Laboratories Inc.
  • DiaGenic ASA
  • G-Biosciences
  • Thermo Fisher Scientific Inc.

第十四章：附录

简介目录
Product Code: BT4407

Market Overview

The Global Central Nervous System Biomarkers Market size reached US$ 4,790.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 9,852.7 million by 2030. The market is exhibiting at a CAGR of 9.7% during the forecast period (2023-2030).

Biomarkers or biological markers are quantitative measurements that provide information about biological processes, a disease state, or a response to treatment. They have the potential to better understand the etiology and pathogenesis of a given disorder, providing researchers and clinicians with valuable insight into diagnosis, treatment, and prognosis for many debilitating disorders and diseases.

The central nervous system biomarkers market is driven by factors such as combining proteomics, genomics, and metabolomic interrogation of CNS tissues, CSF, or blood, and imaging technologies and the development of novel biomarkers.

Market Dynamics

Increasing Demand For Novel Biomarkers

Novel potential biomarkers for CNS disorders include the tau protein, neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1). The tau protein is a neuroaxonal marker located mainly in the white matter of the central nervous system and is reported to be increased in ischemic stroke and cardiac arrest. The NFL is highly accurate in prognostication after cardiac arrest, but it has also been reported to increase in neurodegenerative disorders such as Alzheimer's disease.

GFAP is an astrocytic marker that is produced as part of a neuroprotective mechanism and has been associated with prognosis after head trauma, intracerebral hemorrhage, ischemic stroke, and cardiac arrest. UCH-L1 is a neuronal cell body marker that is crucial for neuroaxonal stability and repair after brain injury.

Technological advances have increased the pace of biomarker discovery, but most are yet to be validated. Incorporating biomarkers into clinical trials and practice will help improve study efficiency and inform advancements in personalized neurology.

High Cost of CNS Biomarker Testing and Diagnostics

With the high cost of the validation process, such as sample collection & storage, government rules and policies are changing since reimbursements do not cover biomarker-mediated therapies that are not considered standard of care.

Even though biomarkers add significant value to tests, refunds are limited. For instance, Medicare, the nation's largest healthcare insurer with more than 50 million beneficiaries, does not fund experimental medicines or most screening and biomarker tests. Therefore, the above factors are expected to hamper the market growth over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has been linked to a range of neurological complications, including cognitive impairment and neurodegenerative changes. For instance, Marshall University, West Virginia, reviewed the diverse neurodegenerative changes associated with COVID-19 and highlighted the importance of major circulating biomarkers, associated with disease progression and severity.

Their literature survey indicated that important CNS proteins, such as GFAP, NfL, and pT181-tau, and various inflammatory cytokines, are altered significantly in COVID-19 patients. The current understanding of the neuropathological changes associated with COVID-19 and the potential use of biomarkers in identifying patients at risk for developing severe forms of the disease is limited.

Russia-Ukraine Conflict Analysis

Risk about the war's long-term impact on the scientific community worldwide and the missed opportunities for research in Ukraine's academic, medical, and scientific disciplines during Russia Ukraine war. Ukraine was testing 251 medicines and devices, according to the FDA's clinical trials database.

According to the clinical trials database, in 2022, over 1,000 medication clinical trials were underway or planned in Ukraine, including 786 in the field of oncology alone. The war has had a negative impact on Russian clinical trial sites, as resources and manpower are not allocated according to priority, leading to worsening CNS care.

Segment Analysis

The global central nervous system biomarkers market is segmented by type, application, disease, end-user, and by region.

Based on Type, Safety Biomarkers Segment Is Expected To Drive The Market Growth

The safety biomarkers segment accounted for the highest market stake accounting for approximately 35.5% of the central nervous system biomarkers market in 2022. Safety biomarkers are expected to dominate the market growth due to increased awareness of health issues such as depression, Parkinson's, and multiple sclerosis. They play a crucial role in preclinical and clinical research trials, with rapid changes in growth measurement, computation, and analysis leading to the explosive growth of the translational research field. For Instance, Donanemab improved cognition and ability to perform activities of daily living in patients with early Alzheimer's disease at 76 weeks.

Geographical Analysis

The Rising CNS Cancer Cases And Increasing R&D Expenditure

North America is estimated to hold around 42.7% of the total market share throughout the forecast period due to rising CNS cancer cases and increased R&D expenditure. According to the American Cancer Society, brain malignancy is the second most common cancer in children and adolescents, where CNS biomarkers are commonly used.

Competitive Landscape

The major global players in the market include: Acumen Pharmaceuticals, Biogen, Alseres Pharmaceuticals, Aposense, Avacta Life Sciences Ltd., Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., DiaGenic ASA, G-Biosciences, and Thermo Fisher Scientific.

Why Purchase the Report?

  • To visualize the global central nervous system biomarkers market segmentation based on type, application, disease, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of central nervous system biomarkers market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global central nervous system biomarkers market report would provide approximately 54 tables, 46 figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Disease
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing demand for Novel Biomarkers
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of CNS Biomarker Testing and Diagnostics
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Safety Biomarkers*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Efficacy Biomarkers
  • 7.4. Validation Biomarkers
  • 7.5. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Drug Discovery & Development*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Personalized Medicines
  • 8.4. Disease Risk Assessment
  • 8.5. Diagnostics
  • 8.6. Others

9. By Disease

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 9.1.2. Market Attractiveness Index, By Disease
  • 9.2. Multiple Sclerosis*
  • 9.3. Alzheimer's Disease
  • 9.4. Parkinson's Disease
  • 9.5. Traumatic Brain Injury
  • 9.6. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Diagnostic Labs
  • 10.3. Clinics
  • 10.4. Hospitals
  • 10.5. Research Centers
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8. China
    • 11.5.9. India
    • 11.5.10. Japan
    • 11.5.11. Australia
    • 11.5.12. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Acumen Pharmaceuticals Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Biogen Inc.
  • 13.3. Alseres Pharmaceuticals Inc.
  • 13.4. Aposense Ltd.
  • 13.5. Avacta Life Sciences Ltd.
  • 13.6. Banyan Biomarkers Inc.
  • 13.7. Bio-Rad Laboratories Inc.
  • 13.8. DiaGenic ASA
  • 13.9. G-Biosciences
  • 13.10. Thermo Fisher Scientific Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us